T cell subsets underlying the rise, fall and recall of the Germinal Center

Informazioni relative al progetto

GC T Subsets

ID dell’accordo di sovvenzione: 101042650

DOI

10.3030/101042650

Data della firma CE 16 Marzo 2022

Data di avvio 1 Settembre 2022

Data di completamento 31 Agosto 2027

Finanziato da

• European Research Council (ERC)

Costo totale

€ 2 129 247,00

Contributo UE

€ 2 129 247,00

Coordinato da

UNIVERSITETET I OSLO
Norway

Periodic Reporting for period 1 - GC T Subsets (T cell subsets underlying the rise, fall and recall of the Germinal Center)

Periodo di rendicontazione: 2022-09-01 al 2025-02-28

Sintesi del contesto e degli obiettivi generali del progetto

The COVID-19 pandemic has underscored significant gaps in our understanding of how durable immunity to rapidly mutating pathogens is established. This immunity is orchestrated within germinal centers (GCs), which are specialized microenvironments where B cells undergo somatic hypermutation, clonal selection, and affinity maturation. These processes result in the generation of high-affinity plasma cells and memory B cells, capable of neutralizing recurring infections and adapting to evolving pathogens. Central to the GC reaction are follicular helper T (Tfh) cells, which facilitate critical cognate interactions with B cells. However, emerging research has identified additional GC-resident T cell subsets with regulatory functions, dynamically influencing GC longevity and termination.
We have previously shown that GC-resident helper T cells can acquire regulatory phenotypes that shape the quality of B cells, impacting antibody diversity and functionality. These findings highlight the importance of understanding how distinct T cell subsets mediate either help or suppression within GCs, driving the differentiation of B cells into high-affinity plasma cells or long-lived memory B cells. This knowledge has profound implications for developing vaccines aimed at eliciting broadly neutralizing antibodies (bnAbs), essential for combating pathogens such as HIV, influenza, and Plasmodium. Additionally, elucidating the molecular pathways governing helper and suppressive T cell functions in GCs provides valuable insights into autoimmune diseases and chronic inflammation, informing the development of T cell-based therapeutic strategies.
Current approaches fail to address the multifaceted roles of T cell subsets within the GC. This ERC StG project aims to uncover the determinants of T cell heterogeneity and their molecular mechanisms, with a specific focus on their impact on B cell quality and antibody functionality.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

In the initial phase of this project, substantial scientific and technical progress has been achieved. Key advancements include elucidating how T cells regulate germinal center (GC) reactions via interaction-driven control mechanisms. This has been accomplished through studies utilizing novel tools for dissecting interaction-driven control of GC cellular subsets, as detailed in the initial project description. In the process, a state-of-the-art intravital two-photon microscopy platform—the first in the country and funded by the ERC StG—was established at the University of Oslo. This advanced imaging system provides high-resolution, spatiotemporal insights into GC T cell dynamics in response to pathogenic challenges.
A novel method for generating monoclonal TCR knock-in mice was developed using AAV and CRISPR/Cas9 genome editing. This transformative approach offers a more efficient, precise, and rapid strategy for creating functional monoclonal TCR mouse models, ensuring physiological TCR expression and accurate T cell differentiation. This significant improvement over traditional transgenic techniques has facilitated the expedited generation of multiple models critical to this project.
Additionally, a GC-driven platform for optimizing therapeutic monoclonal antibodies was established. Leveraging insights into somatic hypermutation and clonal selection within GCs gained during the project period, this system enables the efficient generation of high-affinity therapeutic antibodies targeting challenging antigens.
Overall, this phase has advanced the understanding of T and B cell biology while implementing innovative methodologies grounded in insights gained during this period.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Key Results: GC T cell biology insights from using a novel framework, dissecting contact-mediated control by immune synapse labeling. Germinal Center-Driven Affinity Optimization: Development of a novel platform that utilizes natural somatic hypermutation (SHM) and clonal selection in germinal centers to enhance monoclonal antibody (mAb) affinity. This method circumvents the inefficiencies of traditional methods and enables the generation of monoclonal therapeutic antibodies to elusive targets, such as carbohydrate antigens found in invasive fungal strains. The method presents a novel platform for the generation of therapeutic antibodies. The needs for further development are intellectual property rights (IPR) support and, importantly, support and continued expansion of the Norwegian Transgenic Center (NTS). Development of Knock-In T Cell Models: We have developed a method for rapidly generating monoclonal TCR knock-in mice. Our approach enables the rapid generation of monoclonal TCR mice with physiological TCR expression, providing a transformative tool for studying T cell development, antigen-specific immunity, and disease models. Importantly, this enables the rapid generation of multiple transgenic models for the project. Needs: continued support and expansion from the Norwegian Transgenic Center.